Shares of Editas Medicine Inc. (NASDAQ:EDIT) traded up 4.7% on Friday . The stock traded as high as $18.79 and last traded at $18.60, with a volume of 261,111 shares changing hands. The stock had previously closed at $17.76.

Several analysts have weighed in on the company. Jefferies Group assumed coverage on Editas Medicine in a report on Thursday, June 2nd. They issued a “hold” rating and a $35.00 price target on the stock. Zacks Investment Research raised Editas Medicine from a “sell” rating to a “hold” rating in a report on Wednesday, June 1st. Cowen and Company reissued a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. Finally, Vetr raised Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 price objective on the stock in a report on Monday, May 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $33.50.

The company’s market cap is $660.99 million. The company has a 50-day moving average price of $24.17 and a 200 day moving average price of $29.26.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.54). Equities analysts predict that Editas Medicine Inc. will post ($2.59) earnings per share for the current fiscal year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.